[Form 4] LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock Insider Trading Activity
LifeMD, Inc. (LFMD) reporting person Dennis Wijnker, identified as an officer with the title Chief Technology Officer, reported a change in beneficial ownership on 08/22/2025. The Form 4 shows a grant of 25,000 shares of common stock that vested on that date with an acquisition price recorded as $0, described as performance stock. After the vesting, the reporting person beneficially owned 175,000 shares. The form is signed and dated 08/26/2025. The filing indicates this was a routine vesting event rather than an open-market purchase or sale.
LifeMD, Inc. (LFMD), la persona che presenta la dichiarazione Dennis Wijnker, identificato come dirigente con il titolo di Chief Technology Officer, ha segnalato una variazione nella proprietà effettiva in data 22/08/2025. Il Modulo 4 indica la concessione di 25.000 azioni ordinarie che sono maturate in quella data con un prezzo di acquisizione pari a $0, classificate come azioni legate a obiettivi di performance. Dopo la maturazione, la persona che presenta la dichiarazione deteneva utilmente 175.000 azioni. Il modulo è firmato e datato 26/08/2025. La pratica indica che si è trattato di un evento di maturazione ordinario e non di un acquisto o vendita sul mercato aperto.
LifeMD, Inc. (LFMD), la persona informante Dennis Wijnker, identificado como ejecutivo con el cargo de Chief Technology Officer, notificó un cambio en la propiedad beneficiaria el 22/08/2025. El Formulario 4 muestra la concesión de 25.000 acciones ordinarias que se consolidaron en esa fecha con un precio de adquisición registrado de $0, descritas como acciones basadas en desempeño. Tras la consolidación, la persona informante poseía beneficiariamente 175.000 acciones. El formulario está firmado y fechado el 26/08/2025. La presentación indica que fue un evento rutinario de consolidación y no una compra o venta en el mercado abierto.
LifeMD, Inc. (LFMD)의 보고자 Dennis Wijnker는 Chief Technology Officer라는 직함의 임원으로서 2025-08-22에 실질적 소유권 변동을 보고했습니다. Form 4에는 성과기준 주식으로 분류된 25,000주의 보통주가 해당 일자에 확정(베스팅)되었으며 취득가는 $0로 기록되어 있습니다. 베스팅 후 보고자는 총 175,000주를 실질적으로 보유하게 되었습니다. 해당 서류는 2025-08-26에 서명 및 기재되었습니다. 제출서류는 이는 공개시장에서의 매수·매도가 아닌 정기적인 베스팅 행사였음을 나타냅니다.
LifeMD, Inc. (LFMD), la personne déclarante Dennis Wijnker, identifié comme cadre au titre de Chief Technology Officer, a signalé une modification de la propriété bénéficiaire le 22/08/2025. Le formulaire 4 indique l'attribution de 25 000 actions ordinaires qui ont été acquises à cette date avec un prix d'acquisition enregistré de 0 $, qualifiées d'actions liées à la performance. Après l'acquisition, la personne déclarante détenait de manière bénéficiaire 175 000 actions. Le formulaire est signé et daté du 26/08/2025. Le dépôt précise qu'il s'agissait d'un événement de vesting routinier et non d'un achat ou d'une vente sur le marché ouvert.
LifeMD, Inc. (LFMD)-Meldender Dennis Wijnker, als leitender Angestellter mit dem Titel Chief Technology Officer geführt, meldete am 22.08.2025 eine Änderung des wirtschaftlichen Eigentums. Das Formular 4 weist die Gewährung von 25.000 Stammaktien aus, die an diesem Datum vollständig fällig wurden und mit einem Erwerbspreis von $0 als Performance-Aktien bezeichnet sind. Nach dem Vesting hielt der Meldende wirtschaftlich 175.000 Aktien. Das Formular ist datiert und unterschrieben am 26.08.2025. Die Einreichung weist darauf hin, dass es sich um ein routinemäßiges Vesting-Ereignis und nicht um einen Kauf oder Verkauf am offenen Markt handelte.
- Transparent disclosure of executive equity vesting in a timely Form 4 filing
- Modest ownership stake retained by the officer after vesting (175,000 shares), aligning management with shareholders
- No details provided on the performance conditions or original grant date, limiting assessment of the grant's performance basis
- Acquisition price listed as $0 with no fair-value context disclosed in this form, preventing evaluation of compensation expense or dilution
Insights
TL;DR: Routine insider vesting of performance shares; modest share increase with limited immediate market impact.
The report documents a grant of 25,000 common shares that vested for the Chief Technology Officer on 08/22/2025 at a recorded price of $0, increasing his beneficial ownership to 175,000 shares. This is a compensation-related transaction rather than a purchase or sale. Because the change arises from vested performance stock, it does not reflect an incremental cash investment or disposition and is typically viewed as part of executive compensation plans. The filing contains no information about performance conditions, fair value, or subsequent disposition plans, so assessment of long-term dilution or expense impact cannot be made from this form alone.
TL;DR: Compensation vesting disclosed as required; no regulatory or governance red flags in the filing.
The Form 4 discloses that 25,000 performance shares vested for an officer on 08/22/2025 and the reporting person now beneficially owns 175,000 shares. The transaction is marked as an acquisition via vesting (code A) with an acquisition price of $0, consistent with equity grants settling upon vesting. The form is properly signed. The filing does not indicate any concurrent sales, 10b5-1 plan usage, or amendments that would raise governance concerns. Additional context on grant terms or company-wide dilution would require other filings or proxy disclosures.
LifeMD, Inc. (LFMD), la persona che presenta la dichiarazione Dennis Wijnker, identificato come dirigente con il titolo di Chief Technology Officer, ha segnalato una variazione nella proprietà effettiva in data 22/08/2025. Il Modulo 4 indica la concessione di 25.000 azioni ordinarie che sono maturate in quella data con un prezzo di acquisizione pari a $0, classificate come azioni legate a obiettivi di performance. Dopo la maturazione, la persona che presenta la dichiarazione deteneva utilmente 175.000 azioni. Il modulo è firmato e datato 26/08/2025. La pratica indica che si è trattato di un evento di maturazione ordinario e non di un acquisto o vendita sul mercato aperto.
LifeMD, Inc. (LFMD), la persona informante Dennis Wijnker, identificado como ejecutivo con el cargo de Chief Technology Officer, notificó un cambio en la propiedad beneficiaria el 22/08/2025. El Formulario 4 muestra la concesión de 25.000 acciones ordinarias que se consolidaron en esa fecha con un precio de adquisición registrado de $0, descritas como acciones basadas en desempeño. Tras la consolidación, la persona informante poseía beneficiariamente 175.000 acciones. El formulario está firmado y fechado el 26/08/2025. La presentación indica que fue un evento rutinario de consolidación y no una compra o venta en el mercado abierto.
LifeMD, Inc. (LFMD)의 보고자 Dennis Wijnker는 Chief Technology Officer라는 직함의 임원으로서 2025-08-22에 실질적 소유권 변동을 보고했습니다. Form 4에는 성과기준 주식으로 분류된 25,000주의 보통주가 해당 일자에 확정(베스팅)되었으며 취득가는 $0로 기록되어 있습니다. 베스팅 후 보고자는 총 175,000주를 실질적으로 보유하게 되었습니다. 해당 서류는 2025-08-26에 서명 및 기재되었습니다. 제출서류는 이는 공개시장에서의 매수·매도가 아닌 정기적인 베스팅 행사였음을 나타냅니다.
LifeMD, Inc. (LFMD), la personne déclarante Dennis Wijnker, identifié comme cadre au titre de Chief Technology Officer, a signalé une modification de la propriété bénéficiaire le 22/08/2025. Le formulaire 4 indique l'attribution de 25 000 actions ordinaires qui ont été acquises à cette date avec un prix d'acquisition enregistré de 0 $, qualifiées d'actions liées à la performance. Après l'acquisition, la personne déclarante détenait de manière bénéficiaire 175 000 actions. Le formulaire est signé et daté du 26/08/2025. Le dépôt précise qu'il s'agissait d'un événement de vesting routinier et non d'un achat ou d'une vente sur le marché ouvert.
LifeMD, Inc. (LFMD)-Meldender Dennis Wijnker, als leitender Angestellter mit dem Titel Chief Technology Officer geführt, meldete am 22.08.2025 eine Änderung des wirtschaftlichen Eigentums. Das Formular 4 weist die Gewährung von 25.000 Stammaktien aus, die an diesem Datum vollständig fällig wurden und mit einem Erwerbspreis von $0 als Performance-Aktien bezeichnet sind. Nach dem Vesting hielt der Meldende wirtschaftlich 175.000 Aktien. Das Formular ist datiert und unterschrieben am 26.08.2025. Die Einreichung weist darauf hin, dass es sich um ein routinemäßiges Vesting-Ereignis und nicht um einen Kauf oder Verkauf am offenen Markt handelte.
FAQ
What change did Dennis Wijnker report for LifeMD (LFMD)?
Was the transaction a purchase or sale on the open market?
What is Dennis Wijnker's role at LifeMD according to the filing?
When was the Form 4 signed and filed?
Does the Form 4 provide details on the performance conditions for the granted shares?
